FDA Accepts Arcutis’ Supplemental New Drug Application for Zoryve® (Roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
FDA接受Arcutis的關於Zoryve®(Roflumilast)泡沫治療成人和12歲以上青少年頭皮和全身牛皮癬的補充新藥申請。
FDA Accepts Arcutis’ Supplemental New Drug Application for Zoryve® (Roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
FDA接受Arcutis的關於Zoryve®(Roflumilast)泡沫治療成人和12歲以上青少年頭皮和全身牛皮癬的補充新藥申請。
譯文內容由第三人軟體翻譯。